BioSpace News Archive

Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1

Alentis Therapeutics, the Claudin-1 company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors.

April 13, 2023

·

6 min read

Business

Wheeler Bio Announces Closing of $31 Million Series A Round Supporting its Clinical (CGMP) Drug Substance Manufacturing Facility in Oklahoma City

Wheeler Bio, Inc., a boutique contract development and manufacturing organization specializing in process development and small batch CGMP production of therapeutic antibodies, announced the closing of their Series A financing round.

April 13, 2023

·

4 min read

Biotech Bay

Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023

Genentech, a member of the Roche Group, announced that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, which will be held from April 23-27 in New Orleans, LA.

April 13, 2023

·

12 min read

BioWorld by Clarivate Explores the New Era of Radiopharmaceuticals and its Emergence as a Novel Cancer Therapy

BioWorld™ published by Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, has released a new special series, Radiopharmaceuticals: The next big disrupter.

April 13, 2023

·

4 min read

Business

ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value

ViewRay, Inc. provided a business update and announced preliminary financial results for the quarter ended March 31, 2023.

April 13, 2023

·

9 min read

BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

April 13, 2023

·

6 min read

Drug Development

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced completion of enrollment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of allergic conjunctivitis.

April 13, 2023

·

8 min read

Pharm Country

Premia Spine Completes FDA Site Inspections With No FDA Observations

Premia Spine today announced the U.S. Food and Drug Administration (FDA) has completed four Bioresearch Monitoring (BIMO) inspections as part of the PMA approval process for the TOPS facet joint replacement system.

April 13, 2023

·

3 min read

Drug Development

ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada

ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.

April 13, 2023

·

4 min read

BioMidwest

Saluda Medical Announces $150M Equity Financing Led by Wellington Management with Fidelity Management & Research Company and TPG

Saluda Medical Inc. announced the closing of a US $150 million equity financing round led by new investor Wellington Management, with strong support from current investor Fidelity Management & Research Company and new investor TPG.

April 13, 2023

·

3 min read